Skip to main content

Guaifenesin / potassium guaiacolsulfonate Pregnancy and Breastfeeding Warnings

Brand names: Allfen, Cypex-LA, Humibid LA

Guaifenesin / potassium guaiacolsulfonate Pregnancy Warnings

Guaifenesin-potassium guaiacolsulfonate has been assigned to pregnancy category C by the FDA. Animal studies have not been reported. There are no controlled data in human pregnancy. Guaifenesin-potassium guaiacolsulfonate is only recommended for use during pregnancy when benefit outweighs risk.

See references

Guaifenesin / potassium guaiacolsulfonate Breastfeeding Warnings

There are no data on the excretion of guaifenesin-potassium guaiacolsulfonate into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

Does Guaifenesin/potassium guaiacolsulfonate interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

References for pregnancy information

  1. (2004) "Product Information. Humibid L.A. (guaifenesin-potassium guaiacolsulfonate)." Carolina Pharmaceuticals Inc

References for breastfeeding information

  1. (2004) "Product Information. Humibid L.A. (guaifenesin-potassium guaiacolsulfonate)." Carolina Pharmaceuticals Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer